- Home
- SDA vs REPL Comparison
SDA vs REPL Comparison
Compare SDA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDA
- REPL
- Stock Information
- Founded
- SDA 2007
- REPL 2015
- Country
- SDA China
- REPL United States
- Employees
- SDA N/A
- REPL 479
- Industry
- SDA Blank Checks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SDA Finance
- REPL Health Care
- Exchange
- SDA Nasdaq
- REPL Nasdaq
- Market Cap
- SDA 263.8M
- REPL 239.0M
- IPO Year
- SDA N/A
- REPL 2018
- Fundamental
- Price
- SDA $2.30
- REPL $3.15
- Analyst Decision
- SDA Buy
- REPL Buy
- Analyst Count
- SDA 1
- REPL 10
- Target Price
- SDA $3.50
- REPL $8.25
- AVG Volume (30 Days)
- SDA 102.3K
- REPL 9.2M
- Earning Date
- SDA 09-15-2025
- REPL 08-07-2025
- Dividend Yield
- SDA N/A
- REPL N/A
- EPS Growth
- SDA N/A
- REPL N/A
- EPS
- SDA N/A
- REPL N/A
- Revenue
- SDA $458,905,000.00
- REPL N/A
- Revenue This Year
- SDA $20.77
- REPL N/A
- Revenue Next Year
- SDA $19.32
- REPL N/A
- P/E Ratio
- SDA N/A
- REPL N/A
- Revenue Growth
- SDA 24.15
- REPL N/A
- 52 Week Low
- SDA $2.25
- REPL $2.68
- 52 Week High
- SDA $11.74
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- SDA 33.75
- REPL 24.82
- Support Level
- SDA $2.26
- REPL $2.68
- Resistance Level
- SDA $2.46
- REPL $3.85
- Average True Range (ATR)
- SDA 0.16
- REPL 0.80
- MACD
- SDA 0.00
- REPL -1.03
- Stochastic Oscillator
- SDA 12.50
- REPL 4.45
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.